Broader macroeconomic uncertainty has resulted in continued caution for both investors and acquirers in the in vitro diagnostics sector.

Of the 30 companies included in the list, 24 firms saw their stock prices rise, four saw their share prices decline, and two saw their stock prices remain flat.

The platform will operate at the WA Proteomics Facility, which Proteomics International runs with the University of Western Australia.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

NEW YORK – With its web-based digital pathology platform, Tribun Health said that its whole-slide image management software offers labs workflow improvements with the ability to integrate its system ...

NEW YORK — Canadian diagnostics developer Nanostics said on Thursday that it has received a C$3.8 million (US$2.8 million) grant from Genome Canada and Genome Alberta to boost the adoption of its ...

NEW YORK – The Association for Molecular Pathology on Tuesday published best practice recommendations for the design and validation of clinical tests for homologous recombination deficiency. The ...

NEW YORK – Qiagen expects a new digital PCR partnership program to help build out its in vitro diagnostic menu for the QiAcuityDx clinical digital PCR system.. Although Qiagen officially announced its ...

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.